Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

FDA for the treatment of Huntington's disease.
  • Reported positive clinical data from its Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator of the lectin pathway of the immune system. A Phase 2 clinical program to evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of disorders that occurs in the microcirculation of the body's organs, most commonly the kidney and brain, is expected to begin enrollment in early 2014.
  • Announced that its proprietary Cellular Redistribution Assay technology had "unlocked" six additional Class A orphan G protein-coupled receptors (GPCRs) for drug development, bringing the total number of Class A orphan GPCRs "unlocked" by Omeros to 52. These six orphan GPCRs are linked to a series of important indications, including cardiovascular indications, certain types of cancer and Grave's disease. Omeros also announced that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R). Both of these receptors are established drug targets – GLP-1R for diabetes and PTH-1R for osteoporosis.
  • Financial ResultsTotal operating expenses for the quarter ended September 30, 2013 were $13.6 million and included non-cash expenses of $3.2 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $14.5 million, which included non-cash rent and stock-based compensation expenses of $576,000.

    The decrease in total operating expenses for the quarter ended September 30, 2013 compared to the prior year quarter is primarily due to a litigation settlement expense of $3.95 million recorded in the same period in 2012, which was reimbursed by CCIC in the fourth quarter of 2012. For the quarter ended Septemb
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... , March 5, 2015  UBM Medica US ... a leading online community to help oncologists and ... newest information available regarding the use of targeted ... cancer. March is National Kidney ... few effective adjuvant treatment options for renal cell ...
    (Date:3/5/2015)... e2b teknologies , a premier Sage ERP ... today announced a leading independent multi-specialty physician group practice ... the latest version of Sage 100 ERP . ... kind in the region, the organization has an extensive ... and data accessibility are paramount to their ongoing success. ...
    (Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ... , 3.75% Convertible Senior Notes due May 1, ... per $1,000 principal amount or approximately $5.72 per share, effective ... note is adjusted in connection with the regular quarterly dividend ... stockholders who own shares of PDL on March 5, 2015, the ...
    (Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
    Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
    ... Experience To Antimicrobial Leader.SHREVEPORT, La., March 23 ... in the poultry industry, has joined SteriFx Inc. ... to SteriFx, a leader in developing non-toxic antimicrobial ... defense and other industries. "We,re honored and thrilled ...
    ... DIEGO, March 23 Nereus Pharmaceuticals, Inc., a ... today announced that it is conducting a randomized ... agent (VDA) NPI-2358 in combination with standard chemotherapy ... (NSCLC). This study follows on positive outcomes ...
    ... Based on its recent analysis of ... Sullivan presents Nanopoint, Inc. with the 2009 ... Product Innovation of the Year. The company,s ... sophisticated, on-microscope incubator and integrated fluidics system ...
    Cached Biology Technology:Dan Blackshear Joins SteriFx Inc. 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 2Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 4Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 5
    (Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
    (Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
    (Date:2/5/2015)... 2015 Despite a lack of advancements ... as consumer electronics, automotive, storage and telecommunication has ... (SMT) screen printers. Innovations in electronics and conversion ... the adoption curve up. Meanwhile, sale volumes of ... dispensers are indispensable in the production of complex ...
    Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
    ... "engineered" a mouse that can run on a treadmill ... its supply of acetylcholine, the neurotransmitter essential for muscle ... Neuroscience, could lead to new treatments for neuromuscular disorders ... signals fail to reach the muscles, said Randy Blakely, ...
    ... objects create blurry images in photography, and the same ... constantly in motion, such as the breathing lung. ... a method to stabilize living lung tissue for imaging ... method allowed the team to observe, for the first ...
    ... Maritime transport causes about 4% of global man-made ... as high as Germany,s. There is no regulation ... is currently under discussion in the International Maritime ... Convention on Climate Change (UNFCCC). In respect of ...
    Cached Biology News:Boosting supply of key brain chemical reduces fatigue in mice 2New imaging advance illuminates immune response in breathing lung 2New imaging advance illuminates immune response in breathing lung 3Reducing emissions from shipping: Commission's Joint Research Centre sets out some options 2Reducing emissions from shipping: Commission's Joint Research Centre sets out some options 3
    ... ErbB 2 - BSA and Azide ... tested applications). Antigen: ... KLH, corresponding to C terminal amino ... Entrez GeneID: 2064 ...
    Anti human PPAR gamma2 mouse monoclonal antibody...
    Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
    Mouse monoclonal [1241] to Parainfluenza Virus type 2...
    Biology Products: